Join the Oncology Voice Network. Join for Free
Copy-Paste Development Is a Hidden Industry Risk.

Copy-Paste Development Is a Hidden Industry Risk.


Share This Article


Summary

When development plans are copied from one program to the next without rethinking the strategy, the industry repeats mistakes at scale.

Copy-Paste Development Is a Hidden Industry Risk.

One Idea Worth Acting On.

A protocol is pulled from the archive.

Same eligibility criteria. Same monitoring schedule. Same endpoints.

The team moves fast. The filing goes in on time.

Then the real world responds.

Physicians question whether the endpoints reflect how they actually treat patients today. Payers challenge a value story built against a comparator that is no longer standard of care. Patients drop out at rates the enrollment model never anticipated.

The trial was efficient. The evidence it generated was obsolete before it was filed.

What's Actually Happening

The fastest path forward in oncology development often feels like reuse. If the template worked once, the assumption is it will work again. Eligibility criteria, monitoring requirements, endpoints, operational assumptions — carried forward line by line because removing anything requires justification and keeping it requires nothing.

As Dr. Jedd Wolchok, academic clinical investigator and contributor to Voices of Oncology, describes it: when investigators push back and ask why a requirement is still in the protocol, the answer is almost always the same. It is on our template.

"Change your bloody template," Wolchok says.

The problem is not speed. It is institutional complacency dressed as efficiency. Organizations are optimizing for the regulatory submission process of five years ago while the clinical landscape they are submitting into has moved on entirely.

Why This Matters

Cancer care evolves faster than any other therapeutic area. A protocol designed against the standard of care that existed at the time of its last version may be measuring the wrong comparator, excluding patients who are now routinely eligible, and collecting endpoints that payers and guideline committees no longer find compelling.

Each of those gaps compounds downstream. Slower accrual because the eligibility criteria filter out patients who should qualify. Higher dropout because the monitoring schedule ignores what patients can realistically manage. Weaker reimbursement arguments because the value story was not built against the current treatment landscape.

Terri Conneran, patient advocate and contributor to Voices of Oncology, is precise about the patient-level consequence: the industry must stop relying on copy-paste development and start evaluating the real-life implications of protocols on the patients sitting in clinic today — not the patients who sat in clinic when the original template was written.

Where It Breaks in the Real World

The triplicate EKG requirement that entered protocols a decade ago for a drug class with documented cardiac risk. Still present in protocols for drugs with no cardiac mechanism because nobody challenged it when the template was copied.

The hemoglobin threshold set against healthy volunteer reference ranges. Still filtering out oncology patients whose labs reflect prior treatment — the exact patients the drug was designed for.

Each line has a history. Most teams cannot tell you what it is. The template carries the authority of precedent without the justification that created it.

What Needs to Change

Every eligibility criterion, monitoring requirement, and endpoint needs one question asked of it before the protocol locks: does this still reflect the clinical reality of the patients this trial intends to enroll?

If nobody in the room can answer that question with current clinical evidence — not with "it has always been this way" — the line should not be in the protocol.

That is not a radical position. It is the minimum standard for generating evidence that will still be relevant by the time the drug reaches the market.

The Bottom Line

You cannot build the future of oncology on the templates of the past.

Reusing legacy designs may accelerate regulatory timelines. But it weakens real-world execution, damages payer relevance, and generates evidence about patients who no longer represent the population the drug will serve.

Add Your Voice — Where are you seeing this? What's working — and what's not?

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN